Wellmarker Bio is teaming with Samsung Biologics, a fully integrated CDMO (Contract Development and Manufacturing Organization) in South Korea for the WM-A1-3389 program. Through the contract, WMBIO will receive services as cell line development, upstream and downstream process development, formulation development, preclinical & clinical materials production, quality control and guidance on clinical studies.
The WM-A1-3389 is a novel therapeutic antibody for NSCLC patients with low and negative PD-L1 tumors and has so far demonstrated high immunotherapeutic effect in peripheral blood mononuclear cell (PBMC) and humanized model. According to Dong-Hoon Jin (CEO of Wellmarker Bio), the program is expected to enter its preclinical stage in 4Q 2021 and go into clinic in 3Q 2022. WMBIO is also planning to expand the indication, develop follow-on compounds and is taking a deep account of its use as a combination therapy as well.
Wellmarker Bio is the first spin-off company from Asan Medical center, established in December 22, 2016. The company is developing 9 first-in-class anticancer drugs based on predictive biomarkers. One of the lead assets WM-S1, a small molecule for colon cancer patients, is on phase 1 study in Australia.
Please click on the link below to read the full interview in Korean.